NCT02158091
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 12 with changes below, 12 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 21 words
- Study completion pushed from Jul 2026 to Dec 2026
- Secondary endpoints: details revised at 4 of 9 entries
- Minor Study completion date: Jul 2025 to Jul 2026v22
- Minor Study completion date: Jul 2030 to Jul 2025v18
- Minor Collaborator revisedv16
- Minor Study completion date: Jul 2021 to Jul 2030v12
Show 6 earlier versionsHide 6 earlier versions
- Notable Results first posted: Dec 11, 2018
- Primary endpoints revised (2)
- Start date: Jul 2014 to Jun 27, 2014
- Secondary endpoints: 7 to 9
- Minor Collaborator revisedv9
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 2 of 2 sites
- Minor Enrollment target: 26 to 32
- Site details revised at 1 of 2 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised at 2 of 2 sites
- Notable Eligibility criteria shortened, about 434 words
- Study title shortened, about 8 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Phase I-Dose escalation will occur using a standard 3-3 dose escalation beginning in dose level 1 with dose cohorts and escalation. * Each treatment cycle lasts 28 days (except cycle 1, which is 35 days) during which time IPI-145 will be taken twice daily. The study begins with 1 week of IPI-145 monotherapy. * Fludarabine, cyclophosphamide, rituximab (iFCR) - FCR will subsequently be introduced after 1 week and administered at standard dosing for up to 6 cycles, with dose reductions permitted. IPI-145 will be continued through the course of chemotherapy and for up to 2 years maintenance after completing chemotherapy Phase II - 20 additional patients treated with IPI-145 at the Recommended Phase II Dose (RP2D) + fludarabine, cyclophosphamide, rituximab (FCR) with standard dosing.
Drugs: IPI-145, Fludarabine, Cyclophosphamide, Rituximab
Sites
2 sites in 1 country